US · Healthcare · Biotechnology
EPS came in at -0.27 against a street estimate of -0.33 — a beat of 18.2%.
Analysts rate Greenwich Lifesciences Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $57.00.
| Fund | Stake |
|---|---|
| BlackRock Inc | 3.31% |
| Vanguard Capital Management, LLC | 1.90% |
| Geode Capital Management, LLC | 1.15% |
| State Street Corp | 0.97% |
| Vanguard Portfolio Management, LLC | 0.55% |
| Northern Trust Corp | 0.55% |
| Bank of New York Mellon Corp | 0.33% |
| Vanguard Fiduciary Trust Co | 0.31% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Greenwich Lifesciences Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.